Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Reexamination Certificate
2002-05-31
2010-06-29
Kemmerer, Elizabeth C. (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
C424S085100, C424S085400, C424S651000, C514S503000
Reexamination Certificate
active
07744867
ABSTRACT:
The various embodiments of the present invention are directed to pentavalent antimonials, purified pentavalent antimonials, and pentavalent antimonials that are comprised of an antimonial portion and an organic moeity portion. Alternatively the present invention is directed to agents and methods of screening agents which mimic the activity of pentavalent antimonials, particularly sodium stibogluconate and glucatime. An appropriate organic moeity may be selected based upon a desired interaction (e.g. steric action) with active site of a cellular component (e.g. a PTPase). In a preferred embodiment of the present invention the active site includes a cysteine residue which may be impacted by the compositions of the present invention.
REFERENCES:
patent: 5334374 (1994-08-01), Hartley et al.
patent: 5759837 (1998-06-01), Kuhajda et al.
patent: 5859065 (1999-01-01), Brandes
patent: 6020179 (2000-02-01), Goli
patent: 6143765 (2000-11-01), Tang et al.
patent: 6197306 (2001-03-01), Murali
patent: 6258582 (2001-07-01), Acton
patent: 6388076 (2002-05-01), Mjalli et al.
patent: 6410586 (2002-06-01), Moller et al.
patent: 6569853 (2003-05-01), Borisy et al.
patent: 6693125 (2004-02-01), Borisy et al.
patent: WO 00/21506 (2000-04-01), None
patent: WO 00/21506 (2000-04-01), None
Li et al., Infection and Immunity, 1997, vol. 65(8), pp. 3225-3230.
Gangneux et al., Antimicrobial Agents and Chemotherapy, 1999, vol. 43 (1), pp. 172-174.
Almeida et al., J. Infectious Diseases, 1999, vol. 180, pp. 1735-1737.
Badaro et al., Eur. J. Clin. Microbiol. Infec. Dis., 1994, vol. 13 (supp. 2), pp. S23-S28.
Roberts et al., Am. J. Trop. Med. Hyg., 1996, vol. 55(4), pp. 444-446.
Wick, et a., 2006, Curr. Pharm. Design, vol. 12, pp. 341-349.
Herwaldt et al., Am. J. Trop. Med. Hyg., 1992, vol. 46, pp. 296-306, Abstract.
Li et al., infect. Immun., 1997, 65(8):3225-3230.
Garin et al., Pathol. Biol. (Paris), 1997, 45(1):48-51.
Adachi, M., E.H. Fishcher, J. Ihle, K. Imai, F. Jirik, B. Neel, T. Pawson, S. Shen, M. Thomas, A. Ullrich, and Z. Zhao, Mammaliam SH2-containing protein tyrosin phosphatases. Cell 85:15, 1996.
Alexander, J., K.C. Carter, N. Al-Fasi, A. Satoskar and F. Brombacher, Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur J Immunol, 2000, 30: 2935-43.
Aoki, N. and T. Matsuda. A cytosolic protein-tyrosine phosphatase PTP1B specifically dephosphorylates and deactivates prolactin-activated STAT5a and STAT5b. J Biol Chem, 2000, 275: 29718-26.
Ayub, M. and M.J. Levell. Inhibition of testicular 17 alpha-hydrosylase and 17,20-lyase but not 3 beta-hydroxysteroid dehydrogenase-isomerase or 17 beta-hydroxysteroid oxidoreductase by ketocanazole and other imidazole drugs. J Steroid Biochem, 1987, 28: 521-3.
Bennett, J. M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A. Gralnick, H.R. And Sultan, C. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). a report of the French-American-British Cooperative Group. Ann Intern Med., 103: 460-2, 1985.
Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A. Gralnick, H.R. and Sultan, C. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO) Br J Haematol, 78: 325-9, 1991.
Bergamaschi, G., Carlo-Stella, C., Cazzola, M., De Fazio, F., Pedrazzoli, P., Peverali, F.A. and Della Valle, G. Tumor necrosis factor alpha down-regulates c-myc mRNA expression and induces in vitro monocytic differentiation in fresh blast cells from patients with acute myeloblastic leukemia. Leukemia, 4: 426-30, 1990.
Buchdunger, E., et al., Inhibition of the Abl Protein-Tyrosine Kinase In Vitro an In Vivo by a 2-phenylaminopyrimidine derivative, Cancer Res, 1996, 56: 100-04.
Berman, J. and T.J. O'Leary. Gastroinestinal stromal tumor workshop. Hum Pathol, 2001, 32: 578-82.
Berman, J.D. and M. Grogl. Leishmania mexicana: chemistry and biochemistry of sodium stibogluconate (Pentostam). Exp Parasitol, 1988, 67: 96-103.
Berman, J.D., G. Holz Jr. and D.H. Beach. Efffects of ketoconazole on growth and sterol biosynthesis of Leishmania mexicana promastigotes in culture. Mol Biochem Parasitol, 1984, 12: 1-13.
Berman J.D. and Wyler, D.J. and in vitro model for investigation of chemotherapeutic agents inleishmaniasis. J. Infect. Dis., 142: 83-86, 1988.
Berman, J.D. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev Infect Dis, 10: 560-86, 1988.
Bittorf, T., Seiler, J., Zhang, Z., Jaster, R. and Brock, J. SHP1protein tyrosine phosphatase negatively modulates crythroid differentiation and suppression of apoptosis in J2E erythroleukemic cells. Biol Chem, 380: 1201-9, 1999.
Blanchette, J., Racette, N., Faure, R., Siminovitch, K.A. and Olivier, M. Leishmania-induced increases in activation of macrophage SHP-1 tyrosine phosphatase are associated with impaired IFN-gamma-triggered JAK2 activation. EUR J Immunol, 29: 3747-44, 1999.
Bloomfield, C.D. and Brunning, R.D. The revised French-American-British classificatio of acute myeloid leukemia: is new better? Ann Intern Med, 103: 614-6, 1985.
Blume-Jensen, P. and Hunter, T. Oncogenic kinase signaling. Nature, 411: 355-365, 2001.
Bok, R.A. and E.J. Small. The treatment of advanced prostate cancer with ketoconazole: safety issues. Drug Saf, 1999, 20: 451-8.
Borden E.C. Reducing primary melanoma mortality. Curr Oncol Rep, 2000, 2: 289-91.
Borden, E.C., Lindner, D., Dreicer, R., Hussein, M. and Peereboom, D. Second-generation interferons for cancer: clinical targets. Semin Cancer Biol, 10: 125-44, 2000.
Bradbury, J., Metastasis in colorectal cancer associated with phosphatase expression. Lancet, 358: 1245, 2001.
Breitman, T.R., Selonick, S.E. and Collins, S.J. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc. Nati Acad Sci USA, 77: 2936-40, 1980.
Buick, R.N., R. Pullano, and J.M. Trent, Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res., 45: 3668-76, 1985.
Burke, T., Jr., and Z.Y. Zhang, Protein-tyrosine phosphatases: structure, mechanism, and inhibitor discovery. Biopolymers 47: 225, 1998.
Burshtyn D.N., Scharenberg, A.M., Wagtmann, N., Rajagopalan, S., Berrada, K., Yi, T., Kinet, J.P. and Lone, E. O. Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor. Immunity, 4: 77-85, 1996.
Burshtyn, D.N., Yang, W., Yi, T. and Long, E.O. A novel phosphotyrosine motif with a critical amino acid at position -2 for the SH2 domain-mediated activation of the tyrosine phosphatase SHP- 1. J Biol Chem, 272: 13066-72, 1997.
Cailleau, R., Young, R., Olive, M. and Reeves, W., Jr. Breast tumor cell lines from pleural effusions. J Natl Cancer Inst, 53: 661-74, 1974.
Castrucci, M.R., P. Bilsel, and Y. Kawaoka, Attenuation of influenza A virus by insertion of a foreign epitope into the neuraminidase. J. Virol, 66: 4647-53, 1992.
Carini, C., Hudspith, B.N. and Brostoff, J. Effect of prostaglandins and cyclic nucleotides on growth and immunoglobulin secretion of two 1gE myeloma cell lines. Br J Cancer, 43: 257-60, 1981.
Carter, J.D., B.G. Neel and U. Lorenz. The tyrosine phosphatase SHP-1 influences thymocyte selection by setting TCR signaling thresholds. Int Immunol 11: 1999-2013.
Cates, C.A. et al., Cancer Lett, 110: 49-55, 1992.
Chakravortty, D., Kato, Y., Sugiyama, T., Koide, N., Mu, M. M., Yoshida, T. and Yokochi, T. The inhibitory action of sodium arsenite on lipopolysaccharide-induced nitric oxide production in RAW 267.4 macrophage cells: a role of Raf-1 in lipopolysaccharide signaling. J munol, 166: 2011-7, 2001.
Chawla-Sarkar, M., Leaman, D.W., Jacobs, B.S., Tuthill, R.J., Charrerjee-Kishore, M., Stark, G.R., Borden, E.C., Resistance to interferons in melanoma cells does not correlate with the expression or activation of signal transducer activator of transcription 1 (stat 1). J. Interferon Cytokine Res. 22: 603-13, 2002.
Chen, H., Chang, S., Trub, T. and Neel, B.G. Regulation of colony-stimulating factor 1 receptor signaling by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol. Cell. Biol., 16: 3685-3697,
Kemmerer Elizabeth C.
Tarolli, Sundheim Covell & Tummino LLP
The Cleveland Clinic Foundation
Xie Xiaozhen
LandOfFree
PTPase inhibitors and method of using same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with PTPase inhibitors and method of using same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PTPase inhibitors and method of using same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4176318